Humabs BioMed is a privately owned Switzerland-based company that has been discovering and developing next-generation fully human monoclonal antibody platforms. The technology has been developed within the Institute for Research in Biomedicine led by Professor Antonio Lanzavecchia. Humabs is focusing its platforms on the creation of distinct antibodies to fight infectious, inflammatory and other diseases for development through pharmaceutical partners.
